Acute leukemia (AL) affects patients’ well-being and inflicts substantial symptom burden. We evaluated palliative care needs and symptom burden in adult patients with AL from diagnosis through fourth week of induction chemotherapy.
Methods:
Newly diagnosed adult patients with AL scheduled for curative-intent treatments, prospectively completed Functional Assessment of Cancer Therapy-Leukemia questionnaire at diagnosis and postinduction therapy. Subscale scores identified domains with major needs, with lower scores signifying higher needs, while Leu-subscale assessed leukemia-specific symptom burden.
Results:
One hundred patients were enrolled. Upon diagnosis and four weeks into induction phase, respectively, patients exhibited the lowest scores in physical (17 ± 8.75; 16 ± 11; p < 0.05), functional (16.5 ± 10.75; 11 ± 12.2; p < 0.05), and leukemia-specific (43 ± 16.75; 41.48 ± 11.68; p > 0.05) domains. Predominant symptoms were “getting tired easily” (91%) at diagnosis and “unable to do usual activities” (92.3%) after induction.
Conclusion:
Patients with AL demonstrated substantial physical, functional, and leukemia-specific symptom needs at diagnosis, which intensified postinduction, highlighting the necessity for palliative care integration from diagnosis.
Get full access to this article
View all access options for this article.
References
1.
BispoJAB, PinheiroPS, KobetzEK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harb Perspect Med, 2020; 10(6):a034819; doi: 10.1101/cshperspect.a034819
2.
ManittaV, ZordanR, Cole-SinclairM, et al.The symptom burden of patients with hematological malignancy: A cross-sectional observational study. J Pain Symptom Manage, 2011; 42(3):432–442; doi: 10.1016/j.jpainsymman.2010.12.008
3.
FadulNA, El OstaB, DalalS, et al.Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med, 2008; 11(3):422–427; doi: 10.1089/jpm.2007.0184
4.
OechsleK. Palliative care in patients with hematological malignancies. Oncol Res Treat, 2019; 42(1–2):25–30; doi: 10.1159/000495424
5.
LeBlancTW, El-JawahriA. When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program, 2015; 2015:471–478; doi: 10.1182/asheducation-2015.1.471
6.
HuiD, HannonBL, ZimmermannC, et al.Improving patient and caregiver outcomes in oncology: Team-based, timely, and targeted palliative care. CA Cancer J Clin, 2018; 68(5):356–376; doi: 10.3322/caac.21490
7.
LeBlancTW. Advance care planning and palliative care specialists in malignant hematology and stem-cell transplantation: On why it takes a village. J Oncol Pract, 2018; 14(1):3–5; doi: 10.1200/JOP.2017.026930
8.
PhilipC, GeorgeB, GanapuleA, et al.Acute myeloid leukaemia: Challenges and real world data from India. Br J Haematol, 2015; 170(1):110–117; doi: 10.1111/bjh.13406
9.
RadhakrishnanVS, AgrawalN, BagalB, et al.Systematic review of the burden and treatment patterns of adult and adolescent acute lymphoblastic leukemia in India: Comprehending the challenges in an emerging economy. Clin Lymphoma Myeloma Leuk, 2021; 21(1):e85–e98; doi: 10.1016/j.clml.2020.08.023
10.
FerrellBR, TemelJS, TeminS, et al.Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 2017; 35(1):96–112; doi: 10.1200/JCO.2016.70.1474
11.
TemelJS, GreerJA, MuzikanskyA, et al.Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 2010; 363(8):733–742; doi: 10.1056/NEJMoa1000678
12.
BakitasMA, TostesonTD, LiZ, et al.Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol, 2015; 33(13):1438–1445; doi: 10.1200/JCO.2014.58.6362
13.
JordanK, AaproM, KaasaS, et al.European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. Ann Oncol, 2018; 29(1):36–43; doi: 10.1093/annonc/mdx757
14.
KaasaS, LogeJH, AaproM, et al.Integration of oncology and palliative care: A Lancet Oncology Commission. Lancet Oncol, 2018; 19(11):e588–e653; doi: 10.1016/S1470-2045(18)30415-7
15.
HochmanMJ, YuY, WolfSP, et al.Comparing the palliative care needs of patients with hematologic and solid malignancies. J Pain Symptom Manage, 2018; 55(1):82–88.e1; doi: 10.1016/j.jpainsymman.2017.08.030
16.
ZimmermannC, YuenD, MischitelleA, et al.Symptom burden and supportive care in patients with AL. Leuk Res, 2013; 37(7):731–736; doi: 10.1016/j.leukres.2013.02.009
17.
HowellDA, ShellensR, RomanE, et al.Haematological malignancy: Are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med, 2011; 25(6):630–641; doi: 10.1177/0269216310391692
18.
ChengWW, WilleyJ, PalmerJL, et al.Interval between palliative care referral and death among patients treated at a comprehensive cancer center. J Palliat Med, 2005; 8(5):1025–1032; doi: 10.1089/jpm.2005.8.1025
19.
LoweJR, YuY, WolfS, et al.A cohort study of patient-reported outcomes and healthcare utilization in acute myeloid leukemia patients receiving active cancer therapy in the last six months of life. J Palliat Med, 2018; 21(5):592–597; doi: 10.1089/jpm.2017.0463
20.
El-JawahriA, LeBlancTW, KavanaughA, et al.Effectiveness of integrated palliative and oncology care for patients with acute myeloid leukemia: A randomized clinical trial. JAMA Oncol., 2021; 7(2):238–245; doi: 10.1001/jamaoncol.2020.6343
21.
ShaulovA, AvivA, AlcaldeJ, ZimmermannC. Early integration of palliative care for patients with haematological malignancies. Br J Haematol, 2022; 199(1):14–30; doi: 10.1111/bjh.18286
22.
El-JawahriA, LeBlancT, VanDusenH, et al.Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: A randomized clinical trial. JAMA, 2016; 316(20):2094–2103; doi: 10.1001/jama.2016.16786
23.
RodinG, MalfitanoC, RydallA, et al.Emotion And Symptom-focused Engagement (EASE): A randomized phase II trial of an integrated psychological and palliative care intervention for patients with acute leukemia. Support Care Cancer, 2020; 28(1):163–176; doi: 10.1007/s00520-019-04723-2
24.
ManittaVJ, PhilipJA, Cole-SinclairMF. Palliative care and the hemato-oncological patient: Can we live together? A review of the literature. J Palliat Med, 2010; 13(8):1021–1025; doi: 10.1089/jpm.2009.0267
25.
StrandJJ, LeBlancTW. Palliative care integration in haematological malignancies: Towards a needs-based approach. BMJ Support Palliat Care, 2018; 8(3):289–291; doi: 10.1136/bmjspcare-2018-001611
26.
AbrahamNS, MishraS, BhatnagarS, et al.Quality of life and symptom burden in hematological cancer patients receiving hematopoietic stem cell transplantation: An observational study at Regional Cancer Centre, India. Support Care Cancer, 2024; 32(5):274; doi: 10.1007/s00520-024-08481-8
27.
PatilVM, SinghaiP, NoronhaV, et al.Effect of early palliative care on quality of life of advanced head and neck cancer patients: A phase III trial. J Natl Cancer Inst, 2021; 113(9):1228–1237; doi: 10.1093/jnci/djab020
28.
JayaseelanP, DeodharJ, AshokA, et al.Palliative care needs assessment in patients with metastatic and locally advanced oesophageal cancer. Progress Palliative Care, 2023; 31(3):145–153; doi: 10.1080/09699260.2022.2158287
29.
CellaD, JensenSE, WebsterK, et al.Measuring health-related QoL in leukemia: The Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu) questionnaire. Value Health, 2012; 15(8):1051–1058; doi: 10.1016/j.jval.2012.08.2210
30.
TraskPC, CellaD, BessonN, et al.Health-related QoL of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res, 2012; 36(4):438–442; doi: 10.1016/j.leukres.2011.10.011
31.
PeipertJD, YountSE, EfficaceF, et al.Validation of the Functional Assessment of Cancer Therapy-Leukemia instrument in patients with acute myeloid leukemia who are not candidates for intensive therapy. Cancer, 2020; 126(15):3542–3551; doi: 10.1002/cncr.32977
32.
StalfeltAM. QoL of patients with acute myeloid leukaemia. Leuk Res, 1994; 18(4):257–267; doi: 10.1016/0145-2126(94)90028-0
33.
JieY, WangY, ChenJ, et al.Unmet supportive care needs and its relation to QoL among adult acute leukaemia patients in China: A cross-sectional study. Health Qual Life Outcomes, 2020; 18(1):199; doi: 10.1186/s12955-020-01454-5
34.
WilliamsAL, AultSP, KantarjianMH, et al.Symptom burden in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Blood, 2013; 122(21):2988; doi: 10.1182/blood.V122.21.2988.2988
35.
Leak BryantA, Lee WaltonA, Shaw-KokotJ, et al.Patient-reported symptoms and QoL in adults with AL: A systematic review. Oncol Nurs Forum, 2015; 42(2):E91–E101; doi: 10.1188/15.ONF.E91-E101
36.
ShaulovA, RodinG, PopovicG, et al.Pain in patients with newly diagnosed or relapsed AL. Support Care Cancer, 2019; 27(8):2789–2797; doi: 10.1007/s00520-018-4583-5
37.
RodinG, YuenD, MischitelleA, et al.Traumatic stress in acute leukemia. Psychooncology, 2013; 22(2):299–307; doi: 10.1002/pon.2092
38.
TsatsouI, KonstantinidisT, KalemikerakisI, et al.Unmet supportive care needs of patients with hematological malignancies: A systematic review. Asia Pac J Oncol Nurs, 2021; 8(1):5–17; doi: 10.4103/apjon.apjon_41_20
39.
WangC, YanJ, ChenJ, et al.Factors associated with QoL of adult patients with AL and their family caregivers in China: A cross-sectional study. Health Qual Life Outcomes, 2020; 18(1):8; doi: 10.1186/s12955-020-1269-8
40.
ChenH, ZhouL, FongD, et al.Quality of life and its related-influencing factors in patients with cervical cancer based on the scale QLICP-CE (V2.0). BMC Womens Health, 2024; 24(1):277; doi: 10.1186/s12905-024-03068-1
41.
Balderas-PeñaLM, González-BarbaF, Martínez-HerreraBE, et al.Body composition and biochemical parameters of nutritional status: Correlation with health-related quality of life in patients with colorectal cancer. Nutrients, 2020; 12(7):2110; doi: 10.3390/nu12072110
42.
HauSO, SvenssonM, PeterssonA, et al.Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The CHAMP study. BMC Cancer, 2023; 23(1):1074; doi: 10.1186/s12885-023-11562-2
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
